A phase II study of Chinese patients (pts) treated with <i>nab</i>-paclitaxel (<i>nab</i>-P) plus gemcitabine (Gem) for metastatic pancreatic cancer (MPC).

Lin Shen(Peking University), Rui‐Hua Xu(Sun Yat-sen University), Brian Lu, Guohong Han(Medical Center Hospital), Yanqiao Zhang(Harbin Medical University), Jihui Hao(Tianjin Medical University Cancer Institute and Hospital), Damir Begic, Mingyu Li, Xianjun Yu(Fudan University Shanghai Cancer Center), Liwei Wang(Shanghai First People's Hospital), Jia Chen(Heilongjiang University of Chinese Medicine), Jianming Xu(Chinese PLA General Hospital), Guanghai Dai(Chinese PLA General Hospital), Hongming Pan(Sir Run Run Shaw Hospital), Shujun Yang(Henan Cancer Hospital), Jieer Ying(Chinese Academy of Medical Sciences & Peking Union Medical College)
Journal of Clinical Oncology
February 1, 2016
10.1200/jco.2016.34.4_suppl.327
Cited by 2

Related Papers

Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial
|The Lancet|2010|7.3k
Circular RNA: metabolism, functions and interactions with proteins
|Molecular Cancer|2020|1.6k
Efficacy and safety of regorafenib for advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib (GRID): an international, multicentre, randomised, placebo-controlled, phase 3 trial
|The Lancet|2012|1.4k
Hepatogastroenterology
|Hepatogastroenterology|2012|1.3k
Randomized Phase III KEYNOTE-181 Study of Pembrolizumab Versus Chemotherapy in Advanced Esophageal Cancer
|Journal of Clinical Oncology|2020|1.2k